BPC-157 + TB-500

This blend combines two commonly discussed ‘injury‑recovery’ peptides with complementary actions. BPC‑157 is described as a stable 15‑amino‑acid peptide with broad cytoprotective effects in preclinical models; it is presented as pro‑angiogenic, active on nitric‑oxide pathways, and capable of interacting with growth‑factor systems involved in tissue repair across GI and musculoskeletal tissues. TB‑500 (thymosin β4) is characterized as an actin‑regulating peptide that supports cell migration, wound closure, and anti‑inflammatory responses—key steps in rebuilding damaged soft tissue. The protocol’s rationale is that BPC‑157 helps create a ‘repair‑friendly’ biochemical environment (growth‑factor modulation, NO/angiogenesis, cytoprotection) while TB‑500 emphasizes the physical/structural side of healing (cell movement and remodeling). Together, they are framed as a combined strategy for tendon/ligament/muscle recovery and general soft‑tissue healing, with the main noted tolerability issue being occasional local injection reactions.